Liminal BioSciences Inc. – NASDAQ:LMNL
Liminal BioSciences stock price monthly change
Liminal BioSciences stock price quarterly change
Liminal BioSciences stock price yearly change
Liminal BioSciences key metrics
Market Cap | 27.62M |
Enterprise value | 170.46M |
P/E | -0.53 |
EV/Sales | 425.10 |
EV/EBITDA | 39.41 |
Price/Sales | 647.67 |
Price/Book | 7.17 |
PEG ratio | N/A |
EPS | 0.05 |
Revenue | 492K |
EBITDA | -33.13M |
Income | 354K |
Revenue Q/Q | -28.66% |
Revenue Y/Y | -12.92% |
Profit margin | 124.69% |
Oper. margin | -8170.32% |
Gross margin | 0% |
EBIT margin | -8170.32% |
EBITDA margin | -6735.57% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLiminal BioSciences stock price history
Liminal BioSciences stock forecast
Liminal BioSciences financial statements
| Sep 2022 | 3K | 21.91M | 730500% |
|---|---|---|---|
| Dec 2022 | 241K | -4.77M | -1980.08% |
| Mar 2023 | 136K | -7.64M | -5623.53% |
| Jun 2023 | 112K | -9.14M | -8161.61% |
| Sep 2022 | 53911000 | 13.49M | 25.03% |
|---|---|---|---|
| Dec 2022 | 50459000 | 14.25M | 28.24% |
| Mar 2023 | 39166000 | 10.10M | 25.8% |
| Jun 2023 | 31798000 | 10.32M | 32.46% |
| Sep 2022 | -11.69M | 227K | -5.69M |
|---|---|---|---|
| Dec 2022 | -6.29M | 3.46M | -199K |
| Mar 2023 | -10.34M | 342K | -204K |
| Jun 2023 | -7.77M | 335K | -202K |
Liminal BioSciences alternative data
| Aug 2023 | 251 |
|---|---|
| Sep 2023 | 251 |
| Oct 2023 | 251 |
| Nov 2023 | 251 |
| Dec 2023 | 251 |
| Jan 2024 | 251 |
| Feb 2024 | 251 |
| Mar 2024 | 251 |
| Apr 2024 | 251 |
| May 2024 | 251 |
| Jun 2024 | 251 |
| Jul 2024 | 251 |
Liminal BioSciences other data
| Patent |
|---|
Application SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS Filling date: 9 Apr 2020 Issue date: 30 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2022 17 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 13 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q1 2022 13 May 2022 | Q1 2022 Earnings Call Transcript |
| Q2 2021 17 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Bruce Pritchard BA, CA, FIOD (1973) Chief Executive Officer & Principal Financial Officer | $535,660 |
Mr. Patrick Sartore (1975) Pres | $482,890 |
-
When is Liminal BioSciences's next earnings date?
Unfortunately, Liminal BioSciences's (LMNL) next earnings date is currently unknown.
-
Does Liminal BioSciences pay dividends?
No, Liminal BioSciences does not pay dividends.
-
How much money does Liminal BioSciences make?
Liminal BioSciences has a market capitalization of 27.62M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 37.64% to 401K US dollars.
-
What is Liminal BioSciences's stock symbol?
Liminal BioSciences Inc. is traded on the NASDAQ under the ticker symbol "LMNL".
-
What is Liminal BioSciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Liminal BioSciences?
Shares of Liminal BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Liminal BioSciences's key executives?
Liminal BioSciences's management team includes the following people:
- Mr. Bruce Pritchard BA, CA, FIOD Chief Executive Officer & Principal Financial Officer(age: 52, pay: $535,660)
- Mr. Patrick Sartore Pres(age: 50, pay: $482,890)
-
How many employees does Liminal BioSciences have?
As Jul 2024, Liminal BioSciences employs 251 workers.
-
When Liminal BioSciences went public?
Liminal BioSciences Inc. is publicly traded company for more then 15 years since IPO on 18 Dec 2009.
-
What is Liminal BioSciences's official website?
The official website for Liminal BioSciences is liminalbiosciences.com.
-
Where are Liminal BioSciences's headquarters?
Liminal BioSciences is headquartered at 440 Armand-Frappier Boulevard, Laval, QC.
-
How can i contact Liminal BioSciences?
Liminal BioSciences's mailing address is 440 Armand-Frappier Boulevard, Laval, QC and company can be reached via phone at +1 450 781 0115.
Liminal BioSciences company profile:
Liminal BioSciences Inc.
liminalbiosciences.comNASDAQ
251
Biotechnology
Healthcare
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Laval, QC H7V 4B4
CIK: 0001351172
ISIN: CA53272L1031
CUSIP: 53272L103
